RXRX
Recursion Pharmaceuticals, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers): holder breadth 0.0% · share flow -2.4% · net new positions 0.0% · formula
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 2 | 0 | 77.22K | $312,175 | n/a | n/a |
| Q2 2026 | 102 | -2 | 264.93M | $972.11M | +5 | −7 |
| Q1 2026 | 107 | +3 | 243.54M | $747.81M | +9 | −7 |
| Q4 2025 | 104 | +2 | 261.79M | $1.07B | +4 | −1 |
| Q3 2025 | 16 | -2 | 173.92M | $848.75M | n/a | −3 |
| Q2 2025 | 16 | 0 | 153.65M | $777.46M | n/a | n/a |
| Q1 2025 | 13 | +3 | 87.35M | $462.12M | +3 | n/a |
| Q4 2024 | 10 | 0 | 84.02M | $567.97M | n/a | n/a |
| Q3 2024 | 9 | +2 | 69.10M | $455.38M | +2 | n/a |
| Q2 2024 | 7 | n/a | 63.72M | $477.87M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | The Vanguard Group ✦ (passive) | 36.07M | n/a | $182.52M | 0.0% | n/c | 1 | SEC ↗ ×5 |
| 2 | ARK Investment Management ✦ | 32.99M | -5.2% | $166.92M | 1.2% | ▼ Trim | 5 | SEC ↗ |
| 3 | BlackRock ✦ (passive) | 28.37M | n/a | $143.56M | 0.0% | n/c | 1 | SEC ↗ ×14 |
| 4 | Baillie Gifford ✦ | 24.17M | -0.9% | $122.32M | 0.1% | ▼ Trim | 5 | SEC ↗ ×4 |
| 5 | State Street Global Advisors ✦ (passive) | 11.18M | -14.6% | $56.57M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 6 | Geode Capital Management ✦ (passive) | 7.78M | +20.7% | $39.35M | 0.0% | ▲ Add | 5 | SEC ↗ ×2 |
| 7 | Fidelity (FMR) ✦ | 5.58M | n/a | $28.26M | 0.0% | n/c | 1 | SEC ↗ ×4 |
| 8 | Norges Bank ✦ (passive) | 3.17M | -7.1% | $16.04M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 9 | Citadel Advisors ✦ | 1.31M | -50.5% | $6.65M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 10 | Two Sigma Investments ✦ | 1.17M | +1.3% | $5.91M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 11 | Millennium Management ✦ | 739.41K | +47.3% | $3.74M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 12 | D. E. Shaw & Co. ✦ | 633.40K | +940.0% | $3.21M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 13 | T. Rowe Price ✦ | 281.67K | +25.6% | $1.43M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 14 | Wellington Management ✦ | 94.98K | -11.6% | $480,609 | 0.0% | ▼ Trim | 4 | SEC ↗ ×4 |
| 15 | Marshall Wace ✦ | 86.31K | -74.1% | $436,739 | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 16 | AQR Capital Management ✦ | 13.90K | -91.7% | $70,335 | 0.0% | ▼ Trim | 2 | SEC ↗ ×3 |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 333 holders, 334.81M shares, $1.02B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director · 50.00K sh · $242,000
Director · 25.00K sh · $125,000
Officer, Director · 22.41K sh · $78,822
Director · 30.00K sh · $100,200
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology